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ABSTRACT 
 
 Indirubin, an isomer of indigo, is a reported inhibitor of cyclin-dependent kinases 
(CDKs) and glycogen synthase kinase-3 (GSK-3) as well as an agonist of the aryl 
hydrocarbon receptor (AhR). Indirubin is the active ingredient of a Traditional Chinese 
Medicinal recipe used against chronic myelocytic leukemia. Numerous indirubin analogs 
have been synthesized to optimize this promising kinase inhibitor scaffold. We here 
report on the cellular effects of 7-bromo-indirubin-3’-oxime (7BIO). In contrast to its 5-
bromo- and 6-bromo- isomers, and to indirubin-3’-oxime, 7BIO has only a marginal 
inhibitory activity towards CDKs and GSK-3. Unexpectedly, 7BIO triggers a rapid cell 
death process distinct from apoptosis. 7BIO induces the appearance of large pycnotic 
nuclei, without classical features of apoptosis such as chromatin condensation and 
nuclear fragmentation. 7BIO-induced cell death is not accompanied by cytochrome C 
release neither by any measurable effector caspase activation. Furthermore, the death 
process is not altered either by the presence of Q-VD-OPh, a broad spectrum caspase 
inhibitor, or the overexpression of Bcl.-2 and Bcl-XL proteins. Neither AhR nor p53 is 
required during 7BIO-induced cell death. Thus, in contrast to previously described 
indirubins, 7BIO triggers the activation of non-apoptotic cell death, possibly through 
necroptosis or autophagy. Although their molecular targets remain to be identified, 7-
substituted indirubins may constitute a new class of potential anti-tumor compounds that 
would retain their activity in cells refractory to apoptosis. 
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INTRODUCTION 
 
 In man 518+ protein kinases and 80+ protein phosphatases control the 
phosphorylation of enzymes and structural proteins. Phosphorylation/dephosphorylation 
constitutes one of the most common yet complex post-translational cellular regulatory 
mechanism. Abnormal phosphorylation on specific proteins is observed in essentially all 
pathologies and this has stimulated an extraordinary interest in small molecular weight 
inhibitors of kinases and phosphatases. Protein kinases now constitute the second class of 
targets (after G-protein coupled receptors) used in the drug screening efforts of the 
pharmaceutical industry (reviews in Cohen, 2002; Fischer, 2004; Weinmann and 
Metternich, 2005). These efforts have received considerable support from the remarkable 
success story of Gleevec, one of the first commercial kinase inhibitors. Currently 55 
kinase inhibitors are under clinical evaluation against diseases such as cancers, 
inflammation, diabetes, neurodegeneration, etc...  
Cyclin-dependent kinases (CDKs) play essential functions all along the cell cycle 
and there are multiple examples of dysfunctions of CDKs and their regulators in cancer 
(Vermeulen et al. 2003). Furthermore CDKs are involved in various neurodegenerative 
diseases such as Alzheimer’s, Parkinson’s and Nieman-Pick’s diseases, ischemia and 
traumatic brain injury. A few academic groups, and most pharmaceutical companies, 
have thus invested in the search for pharmacological inhibitors of CDKs (reviews in 
Knockaert et al., 2002; Fischer et al., 2003; Benson et al., 2005; Fischer and Gianella-
Borradori, 2005). Optimization of such inhibitors has been efficiently assisted by their 
co-crystallization with CDK2 (Noble et al., 2004), CDK5 (Mapelli et al., 2005) and 
CDK6 (Lu et al., 2005).  
The bis-indole alkaloid indirubin and its analogs (collectively referred to as 
indirubins) were among some of the early CDK inhibitors to be discovered (Hoessel et 
al., 1999). The red/purple indirubin is an isomer of the blue indigo. Both derive from the 
spontaneous, non-enzymatic dimerisation of isatin and indoxyl, two precursors found 
either free or conjugated to carbohydrates in natural sources. Indirubins can indeed be 
extracted from various indigo dye producing plants (200+ species) (Balfour-Paul, 1998). 
They are also present in the historic “Tyrean purple” dye extracted from various 
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Muricidae mollusks (15+ species) (Meijer et al., 2003; review in Cooksey, 2001). They 
are also extracted from various wild-type and recombinant bacteria (Guengerich et al., 
2004; Wu et al., 2005 and references therein). Finally, indirubin and indigo are 
occasionally present in human urine (Adachi et al., 2001 and references therein). 
Interestingly, indirubin is the active ingredient of a Traditional Chinese Medicine recipe, 
Danggui Longhui Wan, used to treat various diseases including chronic myelocytic 
leukemia (review in Xiao et al., 2002). Besides CDKs, indirubins were found to target 
glycogen synthase kinase -3 (GSK-3) (Leclerc et al., 2001), glycogen phosphorylase b 
(Kosmopoulou et al., 2004) and the aryl hydrocarbon receptor (AhR), also known as the 
dioxin receptor (Adachi et al., 2001; Kawanishi et al., 2003). AhR mediates the effects of 
many xenobiotics such as dioxin and indole-containing compounds (review in Denison & 
Nagy, 2003). Upon binding to xenobiotic-responsive element (XRE), activated AhR 
induces the transcription of numerous genes, including cytochrome P450 CYP1A1, 
p27kip1, myristoyltransferase, etc... (review in Elferink, 2003). Evidence suggests that the 
anti-proliferative effects of indirubins derive from their ability to inhibit CDKs (Marko et 
al., 2001; Damiens et al., 2001). However interaction with AhR and the subsequent 
induction of p27kip1 contributes to a marked arrest in G1 (Knockaert et al., 2004). Finally 
it has been recently shown that some indirubins prevent the phosphorylation and 
subsequent activation of the transcription factor STAT3, leading to a down-regulation of 
survival factors such as survivin and Mcl-1, and subsequent induction of cell death (Nam 
et al., 2005). 
In this article we report on a new sub-family of indirubins, substituted on position 
7. Unexpectedly, despite weak or insignificant inhibitory activity on various classical 
kinase targets of indirubins, 7-bromoindirubin-3’-oxime potently induces a rapid cell 
death distinct from classical apoptosis. The possible mechanisms of action of 7-
substituted indirubins and their potential as anti-tumor agents will be discussed.  
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RESULTS 
 
Different bromoindirubins display different selectivities for kinases 
 In a previous study we observed that a bromine substitution of indirubins on 
position 6 led to compounds with increased selectivity towards GSK-3 (Meijer et al., 
2003; Polychronopoulos et al., 2004). We further extended this work by synthesizing and 
comparing indirubin-3’-oxime (IO) and 5-bromo- (5BIO), 6-bromo- (6BIO) or 7-bromo-
indirubin-3’-oxime (7BIO) (Table 1). Surprisingly, compared to IO, 5BIO and 6BIO, 
7BIO displayed very weak inhibitory activity towards our routine screening kinase 
targets, GSK-3, CDK1/cyclin B, CDK5/p25. Replacement of the bromine substituent by 
chlorine (7CIO) or iodine (7IIO) did not improve the potency of the 7-halogeno-
indirubin-3’oximes, whereas substitution with fluorine (7FIO) enhanced the kinase 
inhibitory potency (Table 1). Finally, substitution of 7BIO on N1 with a methyl group 
(Me7BIO) led to a completely inactive compound, as previously observed with Me6BIO 
(Meijer et al., 2003).  
 We next investigated the selectivity of IO, 5BIO, 6BIO and 7BIO in the 85 
kinase ProQinase selectivity panel (Table 2) 1. This approach first revealed that Aurora 
A-C, FLT3, RET constitute new targets of IO, 5BIO and 6BIO. VEGF-R had been 
described as a target for indirubins (Jautelat et al., 2005). The selectivity panel also 
revealed that, compared to the three other indirubins, 7BIO is a poor kinase inhibitor. 
Only one kinase, FLT3, was inhibited by 7BIO with an IC50 below 1 µM (Table 2) (15 
kinases for IO, 11 for 5BIO, 19 for 6BIO). 7-Br-, 7Cl- and 7I-substituted indirubin-3’-
oximes showed a significant inhibitory activity towards Aurora C, a modest activity on 
Aurora B and little activity, if any, on Aurora A (Table 1), while 7FIO appeared to be 
equipotent on the three Aurora forms. Unexpectedly Me7BIO was found to be rather 
active on Aurora C, but completely inactive on Aurora A and B (Table 1). FLT3 was 
found to be sensitive to all eight indirubins tested including 7MeBIO. The effects of 
indirubins on Aurora kinases and FLT3 will be reported in detail elsewhere. 
                                                 
1 In contrast to the above-mentioned kinase assays performed at a final 15 µM ATP concentration, the 
ProQinase assays are run in the absence of cold ATP. As indirubins act by competing with ATP binding the 
IC50 values are dependent on the assay ATP concnetration, therefore the values of Table 1 and 2 cannot be 
compared directly. 
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Induction of cell death by indirubins 
 We next compared the four indirubins for their ability to induce cell death in 
neuroblastoma SH-SY5Y cells as measured with an MTS reduction assay (Figure 1A). 
Since MTS reduction is occasionally observed under conditions different from cell death, 
we used an independent cell death assay, the lactate dehydrogenase (LDH) release assay 
(Figure 1B). Dose-response curves showed that 7BIO is the most potent compound in 
terms of concentration required to reduce cell survival (MTS reduction) (Figure 1A) or in 
terms of cell death (LDH release) (Figure 1B). However 7BIO’s efficacy was sensitive to 
the concentration of serum, suggesting that it binds to serum proteins (data not shown). 
Different halogens were introduced in position 7 of indirubin-3’-oxime (Figure 2, Table 
1). 7FIO was poorly active on cells compared to the equipotent 7BIO and 7CIO. 7IIO 
was the most potent compound (Figure 2A). These results did not correlate with those 
obtained in the in vitro kinase assays (Table 1). Methylation on N1, leading to Me7BIO, 
totally abolished the cell death inducing ability of 7BIO (Figure 2B). As 7BIO was a 
poor inhibitor of kinases and yet a potent cell death inducer, we decided to investigate the 
effects of this compound in more detail. 
To ascertain that the induction of cell death by 7BIO was not a specific property 
of SH-SY5Y cells, we also used the breast cancer cell line MDA-MB-231 (Figure 3). A 
48 h exposure to 7BIO induced a dose-dependent inhibition of cell proliferation as 
evidenced by direct counting. This effect was poorly if at all reversible by removal of 
7BIO (Figure 3A). We next analyzed the effects of 7BIO on cell cycle distribution 
(Figure 3B). A tendency towards accumulation in G2/M and reduction of G0/G1 was 
observed, as previously described for other indirubins (Hoessel et al., 1999; Damien et 
al., 2001; Marko et al., 2001).  
 
Induction of cell death by 7BIO does not require AhR 
 Indirubins interact with AhR(Adachi et al., 2001). This interaction may contribute 
to the cellular effects of indirubins (Knockaert et al., 2004). However SH-SY5Y cells 
seem to be devoid of AhR (unpublished data). To evaluate the contribution of AhR to the 
cell death effects of 7BIO we made use of two hepatoma cell lines, 5L (AhR +/+) and its 
AhR-deficient sub-clone, BP8 (AhR -/-) (Weiss et al, 1996; Kolluri et al., 1999) 
Ribas et al. Anti-tumor activity of 7-bromoindirubin-3’-oxime 
 8
(Knockaert et al., 2004). We first confirmed that, like 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) (dioxin), both 7BIO and Me7BIO potently enhance the AhR -dependent 
expression of the CDK inhibitory protein p27Kip1 (Figure 4A), as previously reported for 
IO and 6BIO and their methylated counterparts, MeIO and Me6BIO (Knockaert et al., 
2004). No correlation is thus observed between induction of p27Kip1 expression (Figure 
4A) and induction of cell death (Figure 2B). We next analyzed the effects of 7BIO and 
Me7BIO on cell cycle distribution of AhR-/- and AhR+/+ cells. As reported for other 
indirubins, both 7BIO and Me7BIO induced a striking AhR-dependent accumulation in 
G0/G1 (Figure 4B). Finally cell death induction was estimated in both cell lines 
following exposure to increased 7BIO concentrations. The dose-response curves were 
essentially the same (Figure 4C). Altogether these results show that AhR is not involved 
in the cell death inducing properties of 7BIO. 
 
7BIO-induced cell death involves neither p53 nor p21Cip1 nor STAT3 
dephosphorylation 
 We next investigated the involvement of p53 and p21Cip1 in cell death induced by 
the four indirubins (Figure 5). P53 was strongly induced by 5BIO in a time-dependent 
manner in SH-SY5Y cells (Figure 5A-B). Induction of p53 was only modest in cells 
treated with 6BIO and insignificant in cells treated with IO, 7BIO or Me7BIO (Figure 
5A-B). As expected, analysis of p21Cip1 expression under the same conditions showed a 
time-dependent induction by 5BIO (Figure 5C). p21Cip1 expression occurred with some 
delay after p53 stabilization (Figure 5B). IO, 5BIO and 6BIO were roughly equipotent at 
inducing p21Cip1overexpression, while 7BIO and Me7BIO had negligible effects (Figure 
5A). Finally, we tested the effects of 7BIO on wild-type HCT-116 and HCT-116 sub-
clones deprived of p53 (Figure 5E). The dose-response curves were essentially the same. 
Altogether these data suggest that 7BIO-induced cell death does not induce p53 nor 
require its contribution. 
 Tyrosine phosphorylation and subsequent activation of the transcription factor 
STAT3 were recently shown to be inhibited by some indirubins, leading to the down-
regulation of survival factors and subsequent induction of cell death (Nam et al., 2005). 
To examine whether this mechanism is involved in the action of 7BIO, we investigated 
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the effect from IO, 5BIO, 6BIO and 7BIO on the level of tyrosine 705-phosphorylated 
STAT3 in MDA-MB-231 cells (Figure 6). As a positive control, cells were also 
stimulated by interferon α (IFNα). Results show that the basal level of tyrosine 705-
phosphorylated STAT3 in MDA-MB-231 is very low compared to the level reached by 
stimulation with IFNα, yet it is down-regulated by IO, 5BIO and 6BIO but not by 7BIO. 
This suggests that the mechanism of action of 7BIO is not primarily due to an 
inactivation of tyrosine phosphorylated STAT3. 
 
Induction of cell death by 7BIO is much faster than by other indirubins 
 A time-course of SH-SY5Y cell death induction was next performed following 
exposure to 25 µM IO, 5BIO, 6BIO, 7BIO or Me7BIO (Figure 7). Although 5BIO and 
6BIO required 36-48 h to induce 70 % cell death, this level was reached by 12 h with 
7BIO. Almost complete cell death was obtained with 7BIO within 24 h (Figure 7). This 
much faster kinetics suggests that a different mechanism of cell death is occurring in the 
case of 7BIO compared to the other indirubins. Alternatively a sub-population of cells 
may respond to 5BIO and 6BIO as they do to 7BIO, while the vast majority undergoes 
apoptosis. 
 
7BIO induces non-apoptotic cell death 
 To investigate the mechanism of action of 7BIO we first examined, under a 
fluorescence microscope, SH-SY5Y cells exposed to different indirubins following 
bisBenzimide and propidium iodide (PI) staining (Figure 8). First of all, no PI staining 
was observed in control cells and in Me7BIO-treated cells (Figure 8A, 8F), confirming 
the absence of cell death. IO, 5BIO and 6BIO all triggered nuclear fragmentation typical 
of apoptosis, accompanied by secondary necrosis (Figure 8B-8D). These figures were 
never observed in 7BIO-treated cells which, in contrast, displayed numerous large, 
unfragmented pycnotic nuclei (Figure 8E). Such figures were observed only occasionally 
with 5BIO and 6BIO (Figure 8C-8D). These morphological results suggest that 7BIO 
triggers an atypical cell death different from apoptosis. 
 To challenge this possibility, the activity of caspases was assayed in SH-SY5Y 
cells exposed to various concentrations of different indirubins (Figure 9). 5BIO and 
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6BIO, and IO to a lesser extent, triggered a dose- (Figure 9A) and time- (Figure 9B) 
dependent activation of caspase activity. In sharp contrast, neither 7BIO nor Me7BIO 
induced any activation of caspases which remained at the level of control, untreated cells. 
Furthermore, Q-VD-Oph, a general caspase inhibitor (Caserta et al., 2003), had no effect 
on cell death induced by 7BIO (Figure 10), while it reduced the level of cell death 
induced by 5BIO and 6BIO, and IO, to a lesser extent (Figure 10A). The time-course of 
7BIO-induced cell death was unaffected by Q-VD-Oph (Figure 10B). 
 Moreover, 7BIO triggered negligible release of cytochrome C from mitochondria 
(Figure 11). Under the same conditions IO, 5BIO and 6BIO induced the release of 
cytochrome C to levels similar to those reached by standard apoptosis-inducing reagents 
like staurosporine and etoposide. We next examined DNA laddering as a reflection of 
apoptotic cell death. The laddering caused by R-Roscovitine was consistent with the 
reported ability of this compound to induce apoptosis (Ribas and Boix, 2004). 5BIO and 
to a lesser extent 6BIO, also induced internuclesosomal fragmentation, which intensity 
was proportional to the amount of apoptotic cells in the culture (see 
bisBenzimide/propidium iodide staining in Figure 8). In 7BIO treated cells no ladder was 
observed, however most cells were dead. In Me7BIO, IO and DMSO treatments, cell 
death induction was negligible and no laddering was detected.  
Altogether these results show that 7BIO-induced cell death does not induce 
cytochrome C release and does not trigger nor require the activation of caspases, in sharp 
contrast with cell death induced by IO, 5BIO and 6BIO. Thus 7BIO appears to induce a 
cell death pathway which differs from the apoptosis induced by IO, 5BIO and 6BIO. 
 
7BIO-induced cell death is not inhibited by cellular mechanisms able to protect cells 
from apoptosis. 
 To further explore the cell death process triggered by 7BIO, we wondered if 
proved mechanisms of resistance to apoptosis were able to protect cells from 7BIO’s 
effects. SH-SY5Y cells can be differentiated in cell culture by retinoic acid (RA) and this 
differentiation prevents apoptosis triggered by CDK inhibitors, like olomoucine or 
roscovitine (Ribas and Boix, 2004). Similarly, differentiation renders SH-SY5Y cells 
refractory to staurosporine (STS), an established agent used to induce canonical 
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apoptosis. As shown in Figure 12, differentiation had negligible effect on the rates of 
7BIO-induced cell death. 
 Bcl-2 and Bcl-XL proteins are known for their anti-apoptotic effects. In addition, 
their cytoprotective effects have been found to extend beyond apoptosis (Kane et al, 
1995). We previously described that Bcl-2 and Bcl-XL overexpression protects SH-
SY5Y cells from apoptosis triggered by STS (Yuste et al., 2002). As reported, Bcl-XL 
surpassed Bcl-2 at inhibiting STS-induced apoptosis (Figure 12B). However, in a parallel 
time course experiment, neither Bcl-XL nor Bcl-2 overexpression provided any 
significant protection from 7BIO (Figure 12B). Taken together, these results reinforce 
the action of 7BIO as an effective cell killer acting in an apoptosis independent manner.  
 
Non-apoptotic, caspase-independent cell death is a general characteristic of the 
death processes triggered by 7BIO 
 To challenge the generality of the 7BIO effects, we tested 7BIO in two other 
human neuroblastoma derived cell lines, IMR-5 and IMR-32, as well as two 
hematological tumors derived cell lines, Jurkat and HL-60. As shown in Figure 13 (left 
column), 7BIO induced cell death in the same range of concentrations characterized as 
lethal for SH-SY5Y, MDA-MB-231 (breast cancer) and HCT116 (colon cancer) cell 
types. The sensitivity of HL-60 cells (known to be deficient in p53 protein) to 7BIO is 
consistent with the lack of involvement of p53 as described above. 
 We further characterized the cell death process triggered by 7BIO in IMR-5, 
IMR-32, Jurkat and HL-60 cells. Bis-benzimide staining, fluorescence and electron 
microcopy characterizations demonstrated that non-apoptotic cell death was taking place 
as described in SH-SY5Y cells (data not shown). In addition, effector caspase activation 
was assessed at 24 h (Figure 13, right). As expected, 5BIO triggered caspase activation. 
Compared with STS, 5BIO displayed reduced caspase activation, consistent with (1) the 
mixed type of cell death 5BIO induces and (2) less synchronous kinetics of apoptosis 
induction. In contrast DEVDase activity in 7BIO-treated cells fell consistently below the 
background displayed by control, untreated cells. In conclusion, the non-apoptotic, 
caspase-independent type of cell death triggered by 7BIO appears to be an intrinsic 
property of the compound, independent of cell model. 
Ribas et al. Anti-tumor activity of 7-bromoindirubin-3’-oxime 
 12
DISCUSSION 
 
Indirubins have been the object of many chemical modulations in order to 
improve their selectivity profile, kinase inhibitory efficacy and solubility. In particular 
numerous modifications have been carried out on positions 3’, 5’, 6’ on one indole ring 
and 5 or 6 on the other indole ring (Hoessel et al., 1999; Leclerc et al., 2000; Meijer et al., 
2003; Merz et al., 2004; Polychronopoulos et al., 2004; Jautelat et al., 2005). However no 
modifications have ever been reported on position 7. One reason might be that 
substitution at this position almost annihilates inhibitory activity towards key targets of 
indirubins, CDKs and GSK-3. The fast and potent induction of cell death by 7BIO was 
totally unexpected, but provided the impetus to investigate 7-substituted indirubins 
further. Indirubins have been co-crystallized with CDK2 (Hoessel et al., 1999), 
CDK2/cyclin A (Davies et al., 2001), CDK5 (Mapelli et al., 2005), PfPK5, the 
Plasmodium falciparum homolog of CDK1 (Holton et al., 2004), GSK-3ß (Bertrand et 
al., 2003; Meijer et al., 2003; Polychronopoulos et al., 2004), and glycogen 
phosphorylase b (Kosmopoulou et al., 2004). These co-crystal structures suggest that a 
bromine substitution on position 7 would be detrimental to the interaction of indirubins 
with their targets as will be described in detail elsewhere (in preparation). A general 
steric hindrance by the bromine is supported by the fact that IO substituted with a small 
atom such as fluorine is much more active toward kinases than when the position 7 is 
substituted with other halogens (Table 1). This overall unfavorable position 7 substitution 
is confirmed by the kinase selectivity panel (Table 2) which shows that, compared to IO, 
5BIO and 6BIO, 7BIO interacts poorly with protein kinases. However this panel only 
represents 85 out of 518 kinases and the possibility that 7BIO potently inhibits one or 
several unidentified kinases remains open. In addition 7BIO may bind to its targets in an 
orientation which is widely different from that of IO and 6BIO in CDKs and GSK-3.  
Indirubins appear to induce different forms of cell death according to their 
substitutions. We previously reported that a transient exposure to IO triggered a necrotic 
type cell death in nocodazole-synchronized HBL100 cells (Damiens et al., 2001). In 
contrast IO apparently triggered apoptotic type cell death in MCF-7 cells (Marko et al., 
2001). Various 5-substituted indirubins also induce apoptosis as evidenced by PARP 
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cleavage (Nam et al., 2005). This apoptosis appears to be correlated with down-
regulation of survival factors such as survivin and Mcl-1. Induction of apoptosis has also 
been recently described for 5-nitro-indirubin-3’-oxime (Lee et al., 2005). 
Six arguments demonstrate that 7BIO induces cell death by a mechanism distinct 
from apoptosis: [1] a morphological study of dying cells shows that 7BIO induces the 
appearance of large pycnotic nuclei, without classical features of apoptosis such as 
nuclear fragmentation and secondary necrosis (Figure 8); [2] 7BIO does not trigger an 
activation of caspases (Figure 9, 13); [3] the general caspase inhibitor Q-VD-OPh does 
not counteract 7BIO-induced cell death (Figure 10); [4] 7BIO does not induce 
cytochrome C release (Figure 11); [5] 7BIO does not induce DNA fragmentation (Figure 
9); [6] neither Bcl-2 nor Bc-XL overexpression significantly reduce the level of 7BIO-
induced cell death (Figure 12B). 
What is the nature of 7BIO-induced cell death ? Besides apoptosis, a number of 
caspase-independent cell death mechanisms have been described (reviews in Jäättelä, 
2004; Broker et al, 2005). One such pathway is autophagy, a cellular process involved 
both in cell survival and in cell death which requires the family of Atg genes (review in 
Baehecke, 2005). Whether such a pathway is involved in 7BIO-induced cell death is 
currently under investigation. Recently a new caspase-independent cell death process, 
necroptosis, was described that displays some of the characteristics of necrosis and 
activation of autophagy (Degterev et al., 2005). We are currently investigating this 
pathway as a potential mechanism of action of 7BIO. Interestingly it is inhibited by a 
family of substituted indoles called necrostatins (Degterev et al., 2005). Substituents 
(methyl, halogen) at position 7 on necrostatin result in increased inhibitory activity (Teng 
et al., 2005). Given their partial structure similarity it is tempting to speculate that 
necrostatins and 7BIO might share a target which they affect in opposite directions. 
Another description of caspase-independent cell death implies the generation of reactive 
oxygen species (ROS) (Chipuk and Green, 2005). Although preliminary experiments 
suggest that 7BIO does not induce the generation of ROS in vitro (unpublished), we are 
still exploring this possible mechanism of action of 7BIO. Electron microscopy 
examination of 7BIO-treated cells reveals that 7BIO induces a prominent disruption of 
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endoplasmic reticulum without markedly affecting the nucleus (data not shown), 
suggesting that 7BIO acts as a potent reticulum stress inducer. 
 Indirubins interact with and activate AhR leading to the up-regulation of 
cytochrome P450 and p27Kip1 (Adachi et al., 2001; Spink et al., 2003; Knockaert et al., 
2004; Sugihara et al., 2004). 7BIO clearly activates AhR as observed in an in vitro 
luciferase reporter system (unpublished), and confirmed by the AhR-dependent 
expression of p27Kip1 and G1 arrest (Figure 4). However three pieces of evidence suggest 
that AhR is not involved in the cell death process induced by 7BIO: [1] 7BIO triggers 
cell death equally well in AhR-/- and AhR+/+ cells; [2] neuroblastoma SH-SY5Y cells 
express very little if any AhR (unpublished); [3] MeBIO, which is as potent as 7BIO in 
activating AhR, does not induce cell death.  
 7BIO inhibits Aurora C and FLT-3 (Table 1 and unpublished data). Yet Me7BIO, 
which is as potent as 7BIO at inhibiting both kinases, does not trigger cell death (Figure 
2B). 7BIO-induced cell death is therefore unlikely to be a direct consequence of 
inhibition of these two kinases. We also believe that 7BIO action does not involve the 
down-regulation of STAT3 tyrosine phosphorylation and its subsequent inactivation as 
has been suggested for other indirubins (Nam et al., 2005) (Figure 11). 
 Although it is too early to speculate on the potential clinical use of 7-substituted 
indirubins, this new family of indirubins opens a promising research area. Firstly, these 
molecules seem to interact with much less kinases than previously described indirubins 
and thus appear to be more selective (Table 2). Identification of the molecular targets of 
7BIO and 7-substituted indirubins obviously constitutes a high priority. We plan to tackle 
this using affinity chomatography on immobilized 7BIO as described for other kinase 
inhibitors (Bach et al., 2006). Secondly, numerous cancer cells are characterized by the 
development of various mechanisms of resistance to apoptosis (for instance 
overexpression of the Bcl-2 and Bcl-XL oncogenic proteins). Such tumor cells thus 
constitute putative targets for 7-substituted indirubins such as 7BIO, which induce cell 
death through a non-apoptotic pathway and in a Bcl2/Bcl-XL-insensitive way. Such 
indirubins might thus allow the killing of tumor cells resistant to conventional anticancer 
drugs.  
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MATERIAL & METHODS 
 
Chemistry 
General chemistry experimental procedures  
All chemicals were purchased from Aldrich Chemical Co. NMR spectra were recorded 
on Bruker DRX 400; chemical shifts are expressed in ppm downfield from TMS. The 1H-
1H and the 1H-13C NMR experiments were performed using standard Bruker 
microprograms. CI-MS spectra were determined on a Finnigan GCQ Plus ion-trap mass 
spectrometer using CH4 as the CI ionization reagent. Column chomatographies were 
conducted using flash silica gel 60 Merck (40-63 µm), with an overpressure of 300 
mbars. All the compounds gave satisfactory combustion analyses (C, H, N, within ± 0.4% 
of calculated values). 
Indirubin synthesis general procedures 
5-Bromoindirubin (5BI), 7-bromoindirubin (7BI), 7-chloroindirubin (7CI), 7-
iodoindirubin (7II), 7-fluoroindirubin (7FI) and 7-bromo-1-methylindirubin (Me7BI) 
were prepared from 5-bromoisatin, 7-bromoisatin, 7-chloroisatin, 7-iodoisatin, 7-
fluoroisatin, 7-bromo-1-methylisatin, respectively, and 3-acetoxyindol. The synthesis of 
the corresponding indirubins and isatins will be described in details elsewhere 
(Polychronopoulos et al, in preparation)  
5-Bromoindirubin-3’-oxime (5BIO), 7-bromoindirubin-3’-oxime (7BIO), 7-
chloroindirubin-3’-oxime (7CIO), 7-iodoindirubin-3’-oxime (7IIO) 7-fluoroindirubin-3’-
oxime (7FIO) and 1-methyl-7-bromoindirubin-3'-oxime (Me7BIO) were prepared from 
the corresponding indirubins and hydroxylamine hydrochloride. IO and 6BIO were 
synthesized as previously described (Leclerc et al, 2001; Polychronopoulos et al, 2004). 
General procedure for the preparation of the indirubin-oximes 5BIO, 7BIO, 7CIO, 
7IIO, 7FIO and Me7BIO 
The appropriate indirubin derivative 5BI, 7BI, 7CI, 7II, 7FI or Me7BI (1 mmol) was 
dissolved in pyridine (10 mL). With magnetic stirring, hydroxylamine hydrochloride (10 
equiv) was added and the mixture was heated under reflux (120 oC) for 1.5 h. Then the 
solvent was evaporated under reduced pressure and the residue was washed with water 
and cyclohexane to afford quantitatively the corresponding 3’-oxime. 
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5-Bromoindirubin-3’-oxime (5BIO) 
1H NMR (DMSO, 400 MHz, δ ppm, J σε Hz) 13.70 (1H, s, NOH), 11.83 (1H, s, N’-H), 
10.87 (1H, s, N-H), 8.76 (1H, d, J = 2.1 Hz, H-4), 8.27 (1H, d, J = 7.9 Hz, H-4’), 7.44 
(2H, m, H-6’, 7’), 7.28 (1H, dd, J = 8.2, 2.0 Hz, H-6), 7.06 (1H, td, J = 7.9, 2.0 Hz, H-5’), 
6.85 (1H, d, J = 8.2 Hz, H-7); CI-MS m/z 356, 358 (M+H)+ 
7-Bromoindirubin-3’-oxime (7BIO) 
1H NMR (DMSO, 400 MHz, δ ppm, J σε Hz) 13.68 (1H, brs, NOH) 11.90 (1H, s, N’-H), 
10.91 (1H, s, N-H), 8.67 (1H, d, J = 7.8 Hz, H-4), 8.23 (1H, d, J = 7.8, H-4’), 7.42 (2H, 
m, H-6’, 7’), 7.29 (1H, d, J = 7.8 Hz, H-6), 7.06 (1H, t, J = 7.8 Hz, H-5’), 6.90 (1H, t, J = 
7.8 Hz, H-5); CI-MS m/z 356, 358 (M+H)+  
7-Chloroindirubin-3’-oxime (7CIO) 
1H NMR (DMSO, 400 MHz, δ ppm, J σε Hz) 13.70 (1H, brs, NOH) 11.86 (1H, s, N’-H), 
11.09 (1H, s, N-H), 8.62 (1H, d, J = 7.9 Hz, H-4), 8.23 (1H, d, J = 7.6, H-4’), 7.44 (2H, 
m, H-6’, 7’), 7.17 (1H, d, J = 7.9 Hz, H-6), 7.06 (1H, t, J = 7.6 Hz, H-5’), 6.96 (1H, t, J = 
7.8 Hz, H- 5); CI-MS m/z 312, 314 (M+H)+ 
7-Iodoindirubin-3’-oxime (7IIO) 
1H NMR (DMSO, 400 MHz, δ ppm, J in Hz) 13.65 (1H, brs, NOH) 11.87 (1H, s, N’-H), 
10.63 (1H, s, N-H), 8.68 (1H, d, J = 7.8 Hz, H-4), 8.23 (1H, d, J = 7.2, H-4’), 7.47 (1H, 
d, J = 7.8 Hz, H-6), 7.43 (2H, m, H-6’, 7’), 7.06 (1H, t, J = 7.2 Hz, H-5’), 6.76 (1H, t, J = 
7.8 Hz, H- 5); CI-MS m/z 404 (M+H)+ 
7-Fluoroindirubin-3’-oxime (7FIO) 
1H NMR (DMSO, 400 MHz, δ ppm, J σε Hz) 13.61 (1H, brs, NOH) 11.85 (1H, s, N’-H), 
11.19 (1H, s, N-H), 8.44 (1H, d, J = 7.8 Hz, H-4), 8.19 (1H, d, J = 7.5, H-4’), 7.39 (2H, 
m, H-6’, 7’), 7.00 (2H, m, H-5’, 6), 6.90 (1H, m, H-5); CI-MS m/z 296 (M+H)+ 
1-Methyl-7-bromoindirubin-3’-oxime (Me7BIO) 
1H NMR (DMSO, 400 MHz, δ ppm, J σε Hz) 13.70 (1H, brs, NOH), 12.00 (1H, s, N’-H), 
8.81 (1H, d, J = 7.9 Hz, H-4), 8.23 (1H, d, J = 7.9 Hz, H-4’), 7.43 (2H, m, H-6’, 7’), 7.34 
(1H, d, J = 7.9 Hz, H-6), 7.07 (1H, t, J = 7.9 Hz, H-5’), 6.93 (1H, t, J = 7.9 Hz, H-5), 3.68 
(3H, s, N-CH3); CI-MS m/z 370, 372 (M+H)+ 
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Protein kinase assays 
Biochemical Reagents 
Sodium ortho-vanadate, EGTA, EDTA, Mops, ß-glycerophosphate, phenylphosphate, 
sodium fluoride, dithiothreitol (DTT), glutathione-agarose, glutathione, bovine serum 
albumin (BSA), nitrophenylphosphate, leupeptin, aprotinin, pepstatin, soybean trypsin 
inhibitor, benzamidine, histone H1 (type III-S) were obtained from Sigma Chemicals. [γ-
33P]-ATP was obtained from Amersham. The GS-1 peptide 
(YRRAAVPPSPSLSRHSSPHQSpEDEEE) was synthesized by the Peptide Synthesis 
Unit, Institute of Biomolecular Sciences, University of Southampton, Southampton SO16 
7PX, U.K.  
Buffers 
Homogenization Buffer: 60 mM ß-glycerophosphate, 15 mM p-nitrophenylphosphate, 25 
mM Mops (pH 7.2), 15 mM EGTA, 15 mM MgCl2, 1 mM DTT, 1 mM sodium vanadate, 
1 mM NaF, 1 mM phenylphosphate, 10 µg leupeptin/ml, 10 µg aprotinin/ml, 10 µg 
soybean trypsin inhibitor/ml and 100 µM benzamidine. 
Buffer A: 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 25 mM Tris-HCl pH 7.5, 50 µg 
heparin/ml. 
Buffer C: homogenization buffer but 5 mM EGTA, no NaF and no protease inhibitors. 
Kinase preparations and assays 
Kinase activities were assayed in Buffer A or C, at 30 °C, at a final ATP concentration of 
15 µM. Blank values were subtracted and activities calculated as pmoles of phosphate 
incorporated for a 10 min. incubation. The activities are usually expressed in % of the 
maximal activity, i.e. in the absence of inhibitors. Controls were performed with 
appropriate dilutions of dimethylsulfoxide. 
CDK1/cyclin B was extracted in homogenization buffer from M phase starfish 
(Marthasterias glacialis) oocytes and purified by affinity chromatography on p9CKShs1-
sepharose beads, from which it was eluted by free p9CKShs1 as previously described 
(Meijer et al., 1997). The kinase activity was assayed in buffer C, with 1 mg histone H1 
/ml, in the presence of 15 µM [γ-33P] ATP (3,000 Ci/mmol; 10 mCi/ml) in a final volume 
of 30 µl. After 30 min. incubation at 30°C, 25 µl aliquots of supernatant were spotted 
onto 2.5 x 3 cm pieces of Whatman P81 phosphocellulose paper, and, 20 sec. later, the 
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filters were washed five times (for at least 5 min. each time) in a solution of 10 ml 
phosphoric acid/liter of water. The wet filters were counted in the presence of 1 ml ACS 
(Amersham) scintillation fluid. 
CDK5/p25 was reconstituted by mixing equal amounts of recombinant mammalian 
CDK5 and p25 expressed in E. coli as GST (glutathione-S-transferase) fusion proteins 
and purified by affinity chomatography on glutathione-agarose (vectors kindly provided 
by Dr. J.H. Wang) (p25 is a truncated version of p35, the 35 kDa CDK5 activator). Its 
activity was assayed with histone H1 in buffer C as described for CDK1/cyclin B.  
GSK-3α/β was purified from porcine brain by affinity chomatography on immobilized 
axin (Meijer et al., 2003). It was assayed, following a 1/100 dilution in 1 mg BSA/ml 10 
mM DTT, with 5 µl 4 µM GS-1 peptide substrate, in buffer A, in the presence of 15 µM 
[γ-33P] ATP (3,000 Ci/mmol; 10 mCi/ml) in a final volume of 30 µl. After 30 min. 
incubation at 30°C, 25 µl aliquots of supernatant were processed as described above. 
ProQinase protein kinase assays. All protein kinases were expressed in Sf9 insect cells as 
human recombinant GST-fusion proteins or His-tagged proteins by means of the 
baculovirus expression system. Kinases were purified by affinity chomatography using 
either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity and identity of 
each kinase was checked by SDS-PAGE/Coomassie staining and by Western blot 
analysis. A proprietary protein kinase assay (33PanQinase® Activity Assay) was used to 
assay the recombinant enzymes. All kinase assays were performed in 96-well 
FlashPlatesTM from Perkin Elmer/NEN (Boston, MA, USA) in a 50 µl reaction volume 
using a BeckmanCoulter/Sagian robotic system. The reaction cocktail was pipetted in 
four steps in the following order: (i) 20 µl of assay buffer, (ii) 5 µl of ATP solution (in 
H2O), (iii) 5 µl of test compound (in 10 % DMSO) and (iv) 10 µl of substrate / 10 µl of 
enzyme solution (premixed). The assays for all kinases (except for PKC, see below) 
contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 µM Na-
orthovanadate, 1.2 mM DTT, 50 µg/ml PEG20000, 1 µM [γ-33P]-ATP (approx. 5 x 105 
cpm per well). The final DMSO concentration was 1% in all assays. PKC assays 
contained 60 mM HEPES-NaOH, pH 7.5, 1 mM EDTA, 1.25 mM EGTA, 5 mM MgCl2, 
1.32 mM CaCl2, 5 µg/ml phosphatidylserine, 1 µg/ml 1.2 dioleyl-glycerol, 1.2 mM DTT, 
50 µg/ml PEG20000, 1 µM [γ -33P]-ATP (approx. 5 x1005 cpm per well). The reaction 
Ribas et al. Anti-tumor activity of 7-bromoindirubin-3’-oxime 
 19
cocktails were incubated at 30 °C for 80 minutes. The reaction was stopped with 50 µl of 
2 % (v/v) H3PO4, plates were aspirated and washed two times with 200 µl H2O or 200 µl 
0.9 % (w/v) NaCl. Incorporation of 33Pi was determined with a microplate scintillation 
counter (Microbeta, Wallac). With the residual activities (in %) obtained for each 
concentration the compound IC50 values were calculated using Prism 3.03 for Windows 
(Graphpad, San Diego, CA, USA). The model used was “sigmoidal response (variable 
slope)” with parameters “top” fixed at 100 % and “bottom” at 0 %. 
 
Cell biology 
Chemicals and Antibodies 
BisBenzimide (Hoechst 33342) and propidium iodide were obtained from Sigma 
Chemicals. AcDEVDafc and Q-VD-OPh was purchased from MPbiomedicals (Vannes, 
France). Cell Titer 96® kit containing the MTS reagent was purchased from Promega 
(Madison, WI, USA). 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was a kind gift from 
Dr. Steve Safe (Veterinary Physiology and Pharmacology, Texas A&M University, 
College Station, TX77843, USA). The protease inhibitor cocktail was from Roche. IFN-α 
was obtained from R and D systems and all-trans-Retinoic Acid (RA), from Tocris 
(Bristol, UK). Unless otherwise stated, the non-listed reagents were also from Sigma. 
Monoclonal antibodies against p21 WAF1/CIP1 and actin were obtained from Oncogene. 
Antibodies against p27 KIP1 and p53 were purchased from Santa Cruz Biotechnology. 
Monoclonal antibody against cytochrome C and rabbit polyclonal against Bcl-XL were 
provided by BD Biosciences. AntiBcl-2 (clone 124) monoclonal antibody was purchased 
from DAKO. Anti-PhosphoTyr705-STAT3 and anti-STAT3 antibodies were from Cell 
Signalling. The anti-tubulin antibody was from Sigma. 
Cell lines and culture conditions 
The mouse 5L hepatoma cell line (AhR +/+) and BP8 (an AhR -/- subclone) were kindly 
provided by Dr. M. Goëttlicher (Forschungszentrum Karlsruhe, Institute of Genetics, 
76021 Karlsruhe, Germany). They were cultured in Dulbecco’s modified Eagle medium 
(DMEM) (Biowhittaker) supplemented with 2 mM L-glutamine (Eurobio), 10 % fetal 
calf serum (FCS), and gentamycin (Gibco BRL) at 37°C in an atmosphere of 7 % CO2. 
Indirubin or TCDD treatments were performed on 50-60 % confluent cultures at the 
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indicated time and concentrations. Control experiments were carried out using 
appropriate dilutions of DMSO. 
SH-SY5Y, IMR-5 and IMR-32 human neuroblastoma cell lines were grown in DMEM 
medium from (Biowhittaker) plus 2mM L-glutamine from Eurobio (Courtaboeuf, France) 
or DMEM already supplemented with 2mM L-glutamine (Invitrogen, Barcelona, Spain), 
plus antibiotics and a 10% volume of FCS (Invitrogen, Cergy Pontoise, France or 
Barcelona, Spain). SH-SY5Y cell lines permanently transfected with pcDNA3/Bcl-2, 
pcDNA3/Bcl-XL and empty pcDNA3 vectors were grown like their untransfected 
counterparts. However, Geneticin (G-418) selection was maintained in the growing 
cultures before the terminal experiments (Ribas and Boix, 2004). In order to induce 
differentiation, SH-SY5Y cells were cultured on collagen coated plates and treated with 
10 µM RA for five days. 
HL-60 and Jurkat cells were grown in RPMI 1640 medium with 10% FCS and antibiotics 
from Invitrogen (Barcelona, Spain).  
HCT116 human adenocarcinoma cell line was kindly provided by Dr. Vogelstein (The 
Howard Hughes Medical Institute, Sidney Kimmel Comprehensive Cancer Center, The 
Johns Hopkins School of Medicine, Baltimore, MD 21231, USA). HCT116 cells were 
cultured in McCoy's 5A (Biowhittaker) supplemented with antibiotics and 10% FCS. 
General culture conditions were an atmosphere of 5% CO2 and a temperature of 37°C. 
Culture dishes and other plastic disposable tools were supplied by Corning (Corning, NY, 
USA). Indirubin treatments were performed on exponentially growing cultures at the 
indicated time and concentrations. Control experiments were carried also using 
appropriate dilutions of DMSO. 
MDA-MB-231 cells (derived from hormone-independent breast cancer) were cultured in 
DMEM supplemented with 10% FCS. For experiments, these cells were seeded in 24-
well boxes or in 35 mm Petri dishes at appropriate densities (4.104 cells per well for cell 
growth experiments; 105 cells per dish for cell cycle analysis) and exposed to indirubins 
as indicated. 
Cell proliferation and cell cycle analysis 
Propidium iodide (PI) staining was performed as follows. First, SH-SY5Y cells were 
harvested from the culture plates and washed once with PBS (Phosphate Buffered Saline, 
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pH 7.4). Second, 1-2x105 cells were incubated for 15 min in 25 µg/ml propidium iodide, 
10 µg/ml RNase A, and 0.1% Triton X-100. Flow cytometry readings were obtained by 
an EPICS® XL unit from Coulter Científica, SA (Madrid, Spain). Data were processed 
by means of WinMDI (a free software from Joe Trotter) in order to obtain 
monoparametric DNA histograms. Finally, these histograms were analysed with the 
Multi-Cycle software. 
Cell death and cell viability assessments 
Cell death characterization based on nuclear morphology was assessed by double staining 
with 0.05 µg/ml bisBenzimide and 25 µg/ml propidium iodide. Cell viability was 
determined by means of the MTS method. Both procedures have been previously 
described in detail (Ribas and Boix, 2004). For evaluation of DNA laddering, cell DNA 
was extracted and electrophoresed in 1.5% agarose gels to evidence the internucleosomal 
fragmentation typical of apoptosis.  
Caspase assay 
The measurement of caspase activity is based on determining the fluorescence released 
from the AcDEVDafc synthetic substrate after its direct addition to the culture medium, 
detergent lysis, and incubation at 37º. This method is devised to be applied to 96 
multiwell plates. It allows kinetic determinations of caspase activation and the 
characterization of multiple drugs simultaneously. (Ribas et al., 2005). 
Electrophoresis and Western blotting 
Whole cell extracts were obtained in buffer containing 100 mM Tris/HCl pH. 6.8, 1mM 
EDTA, 2% SDS. Following heat denaturation for 3 minutes, proteins were separated by 
10 % SDS-PAGE (0.7 mm thick gels) (p27Kip1) or by 10 % NuPAGE pre-cast Bis-Tris 
polyacrylamide mini gel electrophoresis system (Invitrogen) with MOPS SDS (p53, 
p21Cip1, actin) or MES SDS (cytochrome C) running buffer depending on protein size. 
Proteins were transferred to 0.45 µm nitrocellulose filters (Schleicher and Schuell). These 
were blocked with 5 % low fat milk in Tris-Buffered Saline - Tween-20, incubated for 1 
h with antibodies (anti-p27KIP1: 1:1000; anti-actin: 1:1000; anti-Bcl-2, 1.2000; anti-Bcl-
XL, 1:5000 ; anti-tubulin, 1:4000; anti-STAT3: 1:1000) or overnight at 4°C (anti-p53: 
1:1000; p21Cip1: 1:1000; cytochrome C: 1:1000; anti-actin: 1:5000 (STAT3 experiment); 
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anti-phosphoTyr705-STAT3: 1:1000) and analyzed by Enhanced Chemiluminescence 
(ECL, Amersham).  
To study expression of p53 and p21Cip1, cells were lysed for 30 minutes at 4°C in 
RIPA buffer (150 mM NaCl, 1% NP40, 0.5% deoxycholate, 0.1% SDS and 50 mM Tris-
HCl pH 8.0) supplemented with a protease inhibitor cocktail (Roche). After 
centrifugation (12000g for 10 minutes), the protein concentration was determined in the 
supernatants by the Bradford protein assay (Bio-Rad). To study cytochrome C release 
from mitochondria, a 0.05% digitonin cytosolic extraction was performed (Ribas and 
Boix, 2004). 
 In the STAT3 study, cells were lyzed in 30 mM HEPES(pH 7.5), 10 mM NaCl, 5 
mM MgCl2, 25 mM NaF, 1 mM EGTA, 1 % Triton X-100, 10% glycerol, 2 mM sodium 
orthovanadate, 6.4 mg/mL p-nitrophenylphosphate and protease inhibitor cocktail 
(Roche). 73µg of total proteins was resolved on 10% NuPAGE with MOPS SDS running 
buffer. 
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TABLES 
 
Table 1. Effects of various bromo- substituted indirubins and various 7-halogeno- 
substituted indirubins on three protein kinases. A series of indirubin analogues were 
tested at various concentrations in the kinase assays, as described in the Material and 
Methods section. IC50 values were calculated from the dose-response curves and are 
reported in µM. 
 
NH
N
NH
O
HO 5
     X    Y   Z 
1   H   H   H   (IO)
2   Br  H   H   (5BIO)
3   H   Br  H   (6BIO)
4   H   H   Br  (7BIO)
5   H   H   Cl  (7CIO)
6   H   H   I    (7IIO)
7   H   H   F   (7FIO)
3' Z
X
Y
6
7
NH
N
N
O
HO
8   Me7BIO
3' Br
CH3
 
N° Compound GSK-3 α/β CDK1/ cyclin B 
CDK5/ 
p25 
1 indirubin-3'-oxime (IO) 0.022 0.180 0.100 
2 5-bromoindirubin-3'-oxime (5BIO) 0.016 0.045 0.028 
3 6-bromoindirubin-3'-oxime (6BIO) 0.005 0.320 0.083 
4 7-bromoindirubin-3'-oxime (7BIO) 32 22 33 
5 7-chloroindirubin-3'-oxime (7CIO) 21 3.7 6 
6 7-iodoindirubin-3'-oxime (7IIO) 16 66 77 
7 7-fluoroindirubin-3'-oxime (7FIO) 0.270 1.5 0.510 
8 1-methyl-7-bromoindirubin-3'-oxime (Me7BIO) > 100 > 100 > 100 
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Table 2. ProQinase selectivity profile of IO, 5BIO, 6BIO and 7BIO. The four 
indirubins were tested at various concentrations in 85 kinase assays, as described in the 
Material and Methods section. n.t., not tested. IC50 values, calculated from the dose-
response curves, are reported in µM and underlined according to a gray scale code: 
IC50 value (µM) < 0.1 0.1 - 1 1 - 10 10 - 100 > 100 
 
 
 
 
KINASE IO 5BIO 6BIO 7BIO 
ABL1 >100 >100 3.4 >100 
AKT1 >100 >100 >100 >100 
AKT2 >100 >100 >100 >100 
AKT3 n.t. n.t. >100 >100 
Aurora-A 0.20 0.23 0.43 55 
Aurora-B 1.4 35 1.5 4.7 
Aurora-C 0.57 34 2.3 6.6 
BRK 17 >100 4.6 33 
CDK1/CycB 20 2.1 21 >100 
CDK2/CycA 2.3 0.46 0.71 >100 
CDK2/CycE 2.2 0.12 0.12 >100 
CDK3/CycE 0.15 0.04 0.07 >100 
CDK4/CycD1 0.56 1.33 0.80 >100 
CDK6/CycD1 0.19 0.05 0.17 >100 
CHK1 35 >100 12 >100 
CK2 >100 >100 >100 >100 
COT n.t. n.t. 75 49 
CSK >100 >100 n.t. n.t. 
DAPK1 >100 >100 n.t. n.t. 
EGF-R 102 >100 9.1 27 
EPHA1 53 >100 38 44 
EPHB1 56 >100 n.t. n.t. 
EPHB2 6.1 >100 5.0 33 
EPHB3 >100 >100 34 28 
EPHB4 8.6 >100 3.5 10.0 
ERBB2 >100 >100 >100 26 
ERBB4 >100 >100 >100 >100 
FAK 0.99 >100 12 78 
FGF-R1 0.74 0.83 0.43 36 
FGF-R3 0.38 0.85 0.42 23 
FGF-R4 13 65 1.2 17 
FGR 1.6 >100 0.09 20 
FLT3 0.07 0.02 0.20 0.34 
GSK3-beta 2.5 0.07 0.21 >100 
IGF1-R 5.3 5.6 79 26 
IKK-beta >100 >100 >100 >100 
INS-R 6.6 4.3 >100 >100 
IRAK4 1.8 44 4.8 82 
JAK2 33 >100 >100 >100 
JNK3 25 >100 n.t. n.t. 
KIT 4.3 16 0.76 58 
LCK 41 >100 3.1 >100 
MET >100 >100 >100 >100 
 
KINASE IO 5BIO 6BIO 7BIO 
MST4 73 >100 n.t. n.t. 
MUSK 0.21 31 0.50 >100 
NEK2 >100 >100 >100 >100 
NEK6 >100 >100 >100 >100 
NLK >100 >100 >100 >100 
PAK1 13 11 n.t. n.t. 
PAK2 >100 >100 n.t. n.t. 
PAK4 >100 91 n.t. n.t. 
PBK >100 >100 >100 >100 
PCTAIRE1 >100 >100 >100 >100 
PCTAIRE2 n.t. n.t. 15 >100 
PDGFR-alpha 4.0 9.5 0.52 47 
PDGFR-beta 3.4 3.4 0.88 >100 
PIM1 >100 >100 91 >100 
PIM2 n.t. n.t. >100 >100 
PKC-alpha >100 >100 >100 >100 
PKC-beta1 >100 >100 >100 >100 
PKC-beta2 >100 >100 >100 >100 
PKC-delta >100 >100 >100 65 
PKC-epsilon >100 >100 >100 >100 
PKC-eta >100 >100 >100 >100 
PKC-gamma >100 >100 >100 >100 
PKC-iota >100 >100 >100 >100 
PKC-mu >100 >100 >100 >100 
PKC-theta >100 >100 86 >100 
PKC-zeta >100 >100 >100 96 
PLK1 >100 >100 >100 >100 
PRK1 >100 >100 70 >100 
RET 0.18 2.2 0.05 22 
S6K 82 >100 6.1 >100 
SGK1 0.14 1.6 n.t. n.t. 
SGK3 38 >100 5.8 >100 
SNK >100 >100 >100 >100 
SRC 1.5 17 0.13 27 
SYK 3.0 >100 6.2 85 
TIE2 11 68 13 27 
TSF1 0.87 13 2.9 3.3 
TSK2 >100 >100 >100 >100 
VEGF-R1 1.6 1.6 3.2 >100 
VEGF-R2 0.19 0.25 0.56 23 
VEGF-R3 0.09 0.08 0.22 11 
WEE1 n.t. n.t. >100 >100 
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FIGURE LEGENDS 
 
 
Figure 1. Effects of IO, 5BIO, 6BIO and 7BIO on the survival of SH-SY5Y cells. (A) 
SH-SY5Y cells were exposed for 24 h to increasing concentrations of IO, 5BIO, 6BIO 
or 7BIO. Cell survival was estimated by the MTS reduction assay and is expressed in % 
of survival in untreated cells. Average + s.e. of at least four independent experiments 
with three independent measurements per experiment. (B) A similar experience was 
performed but LDH release was assayed 24 hr after the addition of the indirubins. 
Average + s.e. of two independent experiments with three independent measurements per 
experiment.  
 
Figure 2. Effects of various 7-halogeno-indirubin-3’oxime (A) and 1-methyl-7-
bromo-indirubin-3’oxime (B) on the survival of SH-SY5Y cells. SH-SY5Y cells were 
exposed for 48 h to increasing concentrations of 7-chloro-, 7-iodo-, 7-bromo-, or 7-
fluoro-indirubin-3’oximes (7CIO, 7IIO, 7BIO, 7FIO, respectively) (A) or 1-methyl-7-
bromo-indirubin-3’oxime (Me7BIO) or 7BIO (B). Cell survival was estimated by the 
MTS reduction assay and is expressed in % of survival in untreated cells. Average + s.e. 
of three determinations. 
 
Figure 3. Effects of 7BIO on cell proliferation and cell cycle distribution in MDA-
MB-231 cells. (A) Cells were exposed at time 0 to various concentrations of 7BIO and 
cell numbers were determined at various times. At 48 h, the culture medium was replaced 
by fresh medium devoid of 7BIO. (B) Cells were exposed to various concentrations of 
7BIO for 24 h and their distribution in the various cell cycle phases was determined by 
FACS analysis. 
 
Figure 4. The cytotoxic effect of 7BIO is independent of AhR. (A) Hepatocyte AhR-/- 
(BP8) and AhR+/+ (5L) cells were treated with 0.1 µM TCDD, or 10 µM 7BIO or 
Me7BIO for 24 h or with the vehicle DMSO. The expression level of p27KIP1 was 
determined by Western blotting using a specific antibody. Actin Western blotting was 
used as a loading control. (B) Both 7BIO and Me7BIO induce an Ah-dependent 
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accumulation in G0/G1. 5L and BP8 cells were cultured in the absence (control) or 
presence of DMSO or 10 µM 7BIO or Me7BIO for 24 h, and the cell cycle phase 
distribution was determined by FACS analysis. (C) Both 5L and BP8 cell lines were 
exposed for 24 h to increasing concentrations of 7BIO or Me7BIO. Cell survival was 
estimated by the MTT reduction assay and is expressed in % of survival in untreated 
cells. Average + s.e. of three determinations. 
 
Figure 5. 7BIO does not induce nor require p53 nor p21CIP1 expression. (A) SH-
SY5Y cells were treated with 12.5 µM IO, 5BIO, 6BIO, 7BIO or Me7BIO, 1 µM 
staurosporine or 12.5 µM etoposide for 12 h. Cells were then harvested and proteins were 
resolved by SDS-PAGE followed by Western blotting using antibodies directed against 
p53, p21CIP1 or actin (used as internal loading marker). (B-D) SH-SY5Y cells were 
treated with 12.5 µM 5BIO or 7BIO or 12.5 µM etoposide for various times. Cells were 
then harvested and proteins were resolved by SDS-PAGE followed by Western blotting 
using antibodies directed against p53 (B), p21CIP1 (C) or actin (D). (E) wild-type (●) and 
p53-deprived (○) HCT-116 cells were exposed for 24 h to increasing concentrations of 
7BIO or Me7BIO. Cell survival was estimated by the MTS reduction assay and is 
expressed in % of survival in untreated cells. Average + s.e. of three determinations. 
 
Figure 6. 7BIO effects do not involve down-regulation of STAT3 tyrosine 
phosphorylation. MDA-MB-231 cells were either untreated or treated with 25 µM IO, 
5BIO, 6BIO, 7BIO, or the DMSO carrier for 4 h, or with 100 ng/ml of IFN-α for 5 min. 
Cellular proteins were resolved by SDS-PAGE followed by Western blotting using 
antibodies directed total STAT3 and Tyrosine-phosphorylated STAT3. Western blotting 
with anti-actin antibodies provided a loading marker. 
 
Figure 7. 7BIO induces cell death much faster than other indirubins. SH-SY5Y cells 
were treated with 25 µM IO, 5BIO, 6BIO, 7BIO or Me7BIO for 6, 12, 24, 36 or 48 h. 
Cell survival was assessed by the MTS procedure. Every point is the mean + s.e. of two 
independent experiments with at least three independent measurements per experiment.  
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Figure 8. In contrast to IO, 5BIO and 6BIO, 7BIO induces non-apoptotic cell death 
in SH-SY5Y cells. SH-SY5Y cells were exposed for 24 h to 0.1 % DMSO (control) (A), 
25 µM IO (B), 25 µM 5BIO (C), 10 µM 6BIO (D), 10 µM 7BIO (E) or 10 µM Me7BIO 
(F). Following double staining of DNA with BisBenzimide and propidium iodide, cells 
were examined by fluorescence microscopy. Thick arrows: apoptosis (nuclear 
fragmentation); thin arrows: secondary necrosis; arrow heads: pycnotic nuclei. Scale bar: 
20 µm. 
 
Figure 9. 7BIO does not induce caspase activation. (A) SH-SY5Y cells were treated 
with IO, 5BIO, 6BIO, 7BIO or Me7BIO for 24 h in the range of concentrations shown. 
The value of control untreated cells is placed at time 0. DEVDase activity was measured 
as arbitrary fluorescence units. Every point is the mean + s.e. of at least three independent 
determinations. (B).The time course of effector caspase activity was determined in SH-
SY5Y cells treated with 25µM IO, 5BIO, 6BIO, 7BIO or Me7BIO for 24 h. Every point 
is the mean + s.e. of at least three independent determinations. 
 
Figure 10. 7BIO-induced cell death is not prevented by Q-VD-OPh, a general 
caspase inhibitor. (A) SH-SY5Y cells were treated with 25 µM IO, 5BIO, 6BIO, 7BIO 
or Me7BIO for 48 h in the presence (black bars) or absence (white bars) of 10 µM Q-
VD-OPh, a broad spectrum inhibitor of caspases. Cell survival was assessed by the MTS 
assay. Every point is the mean + s.e. of four independent experiments with three 
independent measurements per experiment. In the control Q-VD-OPh graph only two 
independent experiments were performed. (B) Time-course of 7BIO-induced cell death 
in the absence (○) or presence (●) of 10 µM Q-VD-OPh. Cells were exposed to 25 µM 
BIO at time 0 and cell survival was estimated at different time-points by the MTS assay. 
Each point is the mean + s.e. of at least three independent experiments with three 
independent measurements per experiment. 
 
Figure 11. IO, 5BIO and 6BIO, but not 7BIO, induce cytochrome C release and 
DNA laddering. (A) SH-SY5Y cells were treated with 12.5 µM IO, 5BIO, 6BIO, 7BIO 
or Me7BIO, 0.25 µM staurosporine or 12.5 µM etoposide for 10 h. Cells were then 
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harvested and fractionated into a nuclear pellet and a cytoplasmic supernatant. The latter 
was resolved by SDS-PAGE followed by Western blotting using an anti-cytochrome C 
antibody. The antibody cross-reacts with an irrelevant protein used as an internal loading 
marker. (B) SH-SY5Y cells were treated with DMSO (0.25 %), 25 µM IO, 5BIO, 6BIO, 
7BIO or Me7BIO, or 25 µM (R)-roscovitine for 24 h. Cells were then harvested and 
internucleosomal DNA fragmentation was analyzed by electrophoresis in 1.5 % agarose 
gels. 
 
Figure 12. In contrast to STS-induced apoptosis 7BIO-induced cell death is resistant 
to the protective effects of cell differentiation (A) or Bcl-2 / Bcl-XL overexpression 
(B, C). (A) SH-SY5Y cells were either treated with RA during 5 days to induce 
quiescence and differentiation (white bars) or kept proliferating (black bars). After 24 h 
of treatment with STS (1 µM), 7BIO (25 µM) or racemic Roscovitine (50 µM), cell 
viability was determined by the MTS procedure. Bar value is the mean ± s.e. of at least 6 
independent determinations. (B) SH-SY5Y cells, permanently transfected with the 
vectors pcDNA3/Bcl-XL (●), pcDNA3/Bcl-2 (○) and empty pcDNA3 (■), were treated 
with either STS (2 µM) or 7BIO (25 µM). Cell viability was analyzed by the MTS 
procedure at 9 and 24 h of treatment. In the time course plots, every point is the mean ± 
s.e. of three independent experiments with six independent values per experiment. (C) 
The Bcl-XL and Bcl-2 content of pcDNA3/Bcl-2 (1), pcDNA3/Bcl-XL (2) and 
pcDNA3/empty (3) transfected SH-SY5Y cells was assessed during the viability 
determination experiments by Western blotting. Tubulin content was used to control for 
protein load. 
 
Figure 13. 7BIO induces caspase-independent cell death in four additional cell lines. 
IMR-5, IMR-32, HL-60 and Jurkat cells were challenged with increasing concentrations 
of 7BIO for 24 h and cell viability was determined by the MTS procedure (left). Every 
point is the mean + s.e. of three independent experiments with six independent 
measurements per experiment. The same cell lines were subjected for 24 h to treatments 
with STS (1µM), 5BIO (25 µM), 7BIO (25 µM) or left untreated (U) and the activation 
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of effector caspases (DEVDase activity in arbitrary fluorescent units) was measured 
(right). Bar value is the mean ± s.e. of 6 independent determinations. 
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